Efficacy and safety of PDE5-Is and α-1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs

Sun, Xifeng; Guan, Wei; Liu, Haoran; Tang, Kun; Yan, Libin; Zhang, Yangjun; Zeng, Jin; Chen, Zhiqiang; Xu, Hua; Ye, Zhangqun

doi:10.1186/s12894-018-0345-4

Table 2 Characteristics of the included studies of LUTS/BPH in meta-analysis

From: Efficacy and safety of PDE5-Is and α-1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs

Author	Year	Country	Characteristics of participants					Design	Intervention	No.	Study interval	Comparable index	Jadad score
Author	Year	Country	Age	Cause of LUTS	IPSS	ED	Sick time	Design	Intervention	No.	Study interval	Comparable index	Jadad score
Abolyosr	2013	Egypt	≥45	BPH	≥7	Yes	≥3 months	RCT	Doxazosin 2 mg qd Sildenafil 50 mg qd Combination	50 50 50	4 months	IPSS, PVR, Qmax, IIEF, QoL	4
Kaplan	2007	USA	50–76	BPH	17.4(mean)	Yes	/	RCT	Alfuzosin 10 mg qd Sildenafil 25 mg qd Combination	20 21 21	12 weeks	IPSS, Qmax, Nocturia, PVR, IIEF, AEs	3
KIM	2011	Korea	≥45	BPH	≥13	/	≥6 months	RCT	Tadalafil 5 mg qd	51 49	12 weeks	IPSS, QoL, Nocturia, Qmax, PVR, AEs	5
KIM	2011	Korea	≥45	BPH	≥13	/	≥6 months	RCT	Tamsulosin 0.2 mg qd	51 49	12 weeks	IPSS, QoL, Nocturia, Qmax, PVR, AEs	5
Singh	2014	India	≥45	BPH	> 8	/	≥6 months	RCT	Tamsulosin 0.4 mg qd Tadalafil 10 mg qd Combination	45 44 44	3 months	IPSS, Qmax, PVR, QoL, IIEF, AEs	3
Tuncel	2010	Turkey	47–77	BPH	> 12	Yes	≥6 months	RCT	Sildenafil 25 mg qd 4d/week	20	8 weeks	IPSS, Qmax, PVR, QoL, IIEF	4
Tuncel	2010	Turkey	47–77	BPH	> 12	Yes	≥6 months	RCT	Tamsulosin 0.4 mg qd Combination	20 20	8 weeks	IPSS, Qmax, PVR, QoL, IIEF	4
Bechara	2008	Argentina	> 50	BPH	> 12	/	≥6 months	RCCT	Tamsulosin 0.4 mg qd + tadalafil 20 mg qd	27	45 days	IPSS, Qmax, PVR, QoL, AEs	5
Bechara	2008	Argentina	> 50	BPH	> 12	/	≥6 months	RCCT	Tamsulosin 0.4 mg qd + placebo	27	45 days	IPSS, Qmax, PVR, QoL, AEs	5
Liguori	2009	Italy	50–75	BPH	> 8	Yes	≥6 months	MRCT	Alfuzosin 10 mg qd Tadalafil 20 mg qd Combination	18 19 21	12 weeks	IPSS, Qmax, PVR, QoL, IIEF, AEs	3
Ng	2009	China	50–80	BPH	/	Yes	/	RCCT	Doxazosin0.4–0.8 mg qd + vardenafil 10 mg qd	37	2 days	AEs	6
Ng	2009	China	50–80	BPH	/	Yes	/	RCCT	Doxazosin0.4–0.8 mg qd + placebo	37	2 days	AEs	6
Regadas	2013	Brazil	> 45	BPH	> 14	/	≥6 months	RCT	Tamsulosin 0.4 mg qd + tadalafil 5 mg qd	20	30 days	IPSS, Qmax, QoL, AEs	5
Regadas	2013	Brazil	> 45	BPH	> 14	/	≥6 months	RCT	Tamsulosin 0.4 mg qd	20	30 days	IPSS, Qmax, QoL, AEs	5
Gacci	2012	Italy	40–80	BPH	≥12	Yes/No	/	RCT	Vardenafil 10 mg qd + tamsulosin 0.4 mg qd	30	2 weeks	IPSS, Qmax, PVR, QoL, IIEF, AEs	5
Gacci	2012	Italy	40–80	BPH	≥12	Yes/No	/	RCT	Tamsulosin 0.4 mg qd + Placebo	30	2 weeks	IPSS, Qmax, PVR, QoL, IIEF, AEs	5
Kumar	2014	India	> 50	BPH	≥8	/	/	RCT	Alfuzosin 10 mg qd	25	12 weeks	IPSS, IIEF, Qmax, PVR, QoL	5
									Tadalafil 10 mg qd	25
									Combination	25
Jin	2011	China	50–75	BPH	≥10	Yes	/	MRCT	Doxazosin 4 mg qd + sildenafil 25–100 mg on demand	168	6 months	IPSS, QoL, IIEF, AEs	3
Jin	2011	China	50–75	BPH	≥10	Yes	/	MRCT	Sildenafil 25–100 mg on demand	82	6 months	IPSS, QoL, IIEF, AEs	3

LUTS lower urinary tract symptom, BPH benign prostatic hyperplasia, ED erectile dysfunction, Qmax maximum flow rate, IPSS international prostase Symptom score, PVR postvoid residual urine, QoL quality of life, IIEF international index of erectile function, / not available, AEs adverse events, RCT randomized controlled trial, MRCT multicenter randomized controlled trial, RCCT randomized controlled crossover trial

Back to article page

ISSN: 1471-2490

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Urology

Contact us